Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound
NCT ID: NCT01579227
Last Updated: 2018-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
101 participants
OBSERVATIONAL
2012-01-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective 1, (topical only - referred to as "TOP") - Topical application of Tocotrienol (TCT) vs placebo in bilateral punch biopsy
Objective 2, (oral and topical - referred to as "OTOP") - Combined oral supplementation and topical application of tocotrienol (TCT) vs placebo in bilateral punch biopsy
Objective 3, (topical only - referred to as "TAM") - Topical application of tamoxifen vs placebo in bilateral punch biopsy.
Objective 4, (topical only to normal skin) - Topical application of TCT vs placebo on bilateral lets on normal skin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars
NCT00700791
Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol
NCT00678834
13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
NCT00002586
Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection
NCT06962657
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
NCT02911688
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* TCP are mainly found in green leafy vegetables while TCT are the primary vitamin E of seeds, including cereal grains such as wheat, rice, and barley.
* Vitamin E is thought to improve wound healing by inhibiting collagen synthesis and attenuating fibroblast proliferation and inflammation. However, outcomes based scientific literature on the therapeutic efficacy of vitamin E in skin wound closure is scant and has primarily focused on TCP.
* Oral supplementation of TCP showed modest improvement in rodent wound closure, but the relevance of oral TCP supplementation in rats already receiving high dose vitamin E in a standard laboratory is questionable.
* Topical TCP on surgical wounds of children have been shown to improve wound healing; yet no mechanistic basis for the observed effect was described.
* Preliminary observations from the PI's active IRB protocol to test TCT in scar appearance of surgical wounds led us to evaluate the potential of TCT vitamin E to improve wound closure in healthy subjects. To date, the therapeutic efficacy of TCT in either topical (TOP) or oral with topical (OTOP) applications for skin wound healing remains to be reported.
* Preliminary observations also made show down-regulation of microRNA-200b supports cutaneous angiogenesis, the most important step in cutaneous wound healing. Tamoxifen silences mircroRNA-200b and later work has recognized that under non-neoplastic conditions, tamoxifen may induce angiogenesis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1-TOP group 1
TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
No interventions assigned to this group
TOP group 2
TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
No interventions assigned to this group
OTOP group-1
OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
Topical Tocotrienol (TCT)
Natural Form Vitamin E topical cream(TCT)
Oral Tocotrienol Capsules (TCT)
Natural Form Vitamin E Oral capsules (TCT)
Placebo cream
Placebo cream
placebo capsule
placebo capsule
OTOP group-2
OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
Topical Tocotrienol (TCT)
Natural Form Vitamin E topical cream(TCT)
Oral Tocotrienol Capsules (TCT)
Natural Form Vitamin E Oral capsules (TCT)
Placebo cream
Placebo cream
placebo capsule
placebo capsule
TAM Group 1
TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
Tamoxifen Cream
Tamoxifen cream
Normal Skin
Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
Tamoxifen Cream
Tamoxifen cream
Placebo cream
Placebo cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Topical Tocotrienol (TCT)
Natural Form Vitamin E topical cream(TCT)
Oral Tocotrienol Capsules (TCT)
Natural Form Vitamin E Oral capsules (TCT)
Tamoxifen Cream
Tamoxifen cream
Placebo cream
Placebo cream
placebo capsule
placebo capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-smoker - having quit at least 3 months prior to enrollment
* Non-diabetic
* Non-pregnant or non-breastfeeding - verbal assent.
* If a female subject of childbearing age misses her menstrual period after the start of the study, she will inform the investigators and be given a pregnancy test to ensure, for safety reasons, that she is not pregnant. If she is pregnant, she will discontinue participation in the study.
* No current use of OTC medications or other form of supplements containing vitamin-E
Exclusion Criteria
* Alcohol or drug abuse
* unable to provide informed consent
* Therapeutically anti-coagulated
* Prisoner
* Currently prescribed immunosuppressant medication
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Carotech Inc.
INDUSTRY
Chandan K Sen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chandan K Sen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chandan K Sen, PhD
Role: PRINCIPAL_INVESTIGATOR
Ohio State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ohio State University Medical Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011H0286
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.